Results from a trial show that some men receiving radiation therapy for prostate cancer can have their treatment compressed into just 5 sessions, compared with the usual 20 or more. The shorter stereotactic body radiotherapy (SBRT) compared well with other common regimens given over longer periods.
Black people with cancer are much less likely to join clinical trials than White people. Results from a new study may help explain why. They might also help research staff talk with and recruit more Black participants.
In a trial with nearly 1,000 patients, treatment with nivolumab (Opdivo) and the chemotherapy regimen AVD was better at killing cancer and keeping it at bay than AVD and brentuximab (Adcetris), the current standard treatment. The nivolumab combination also had fewer side effects.
A randomized clinical trial comparing two types of surgery in people with localized muscle-invasive bladder cancer found that surgery to remove a larger group of lymph nodes did not improve survival, compared with standard lymph node surgery.
Clinical Trials Information for Patients and Caregivers
This recently updated page explains what clinical trials are, why they are important, and what different types of clinical trials are available to people with cancer.
This page explains how clinical trials are designed to work in phases that follow strict guidelines, including who can participate. Other topics discussed include randomization and bias, use of placebos in cancer clinical trials, research teams, and where trials take place.
This phase 2 trial is testing treatment with one or two approved immunotherapy drugs in people with colorectal or gastroesophageal cancer who may require surgery. People in the trial will receive nivolumab with or without ipilimumab (Yervoy) with the intent to kill enough cancer that they can skip surgery.
This phase 1/2 clinical trial is testing two chemotherapy drugs combined with an experimental drug. The new drug targets a cancer-related protein to treat young people with Ewing sarcoma or rhabdomyosarcoma that has come back or not responded to treatment. Doctors will determine if the experimental combination is safe and helps shrink or kill these tumors.
In this phase 2 trial, people between the ages of 1 and 25 with B-cell acute lymphoblastic leukemia will get a new kind of lab test to determine their chances of relapse after a blood stem cell transplant. Those with a low chance of relapse can have chemotherapy before their transplant but skip total body radiation. Researchers want to see if the people receiving chemotherapy have similar event-free survival after two years.
